Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,longTermDebt,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,currency,epsCurrentYear,market,shortName,exchange,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,exchangeDataDelayedBy,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,CYTK,16489000.0,71738096,,,-61554000,,-61554000,21197000,-33600000,-54797000,-54797000,,-6944000,,,,0,2843000,57640000,36443000,-6757000,,-61554000,-61554000,1117403000.0,547813000.0,16489000.0,1004000.0,564302000.0,72000.0,-1100964000.0,258790000.0,-22000.0,6453000.0,37154000.0,61766000.0,11250000.0,-22000.0,119948000.0,364229000.0,73672000.0,313147000.0,2701000.0,127886000.0,14928000.0,27673000.0,1667000.0,18881000.0,3175000.0,15210000.0,-7440000.0,-29496000.0,543000.0,1813000.0,3175000.0,12825000.0,-8792000.0,,,302463000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,32.9,1630503360,-0.069999695,32.73,32.94,32.56,34479,-10.31348,0.948,28.89889,4.001112,0.1384521,24.313116,8.586885,0.35317913,2360183552,-10.64725,34.704643,15,America/New_York,EDT,False,False,USD,-3.19,us_market,"Cytokinetics, Incorporated",NMS,REGULAR,2,-0.2123133,32.56 - 32.94,32.97,32.0,34.51,18,31,finmb_27315,NasdaqGS,"Cytokinetics, Incorporated",USD,1812484,877283,18.190002,1.2365739,14.71 - 34.32,-1.4199982,-0.04137524,14.71,34.32,1620331200,1635872400,0,1636405200,-2.0,-3.09,-14400000,1.41,,,34.32,14.71,28.9,24.31,1.81M,877.28k,71.74M,,83.05M,4.76%,93.86%,11.41M,3.13,16.08%,13.67%,9M,,,,,,0.00%,,,1:6,"Jun 24, 2013","Dec 30, 2020","Jun 29, 2021",-269.48%,-219.08%,-19.87%,,57.8M,0.82,-20.90%,-41.12M,-124.54M,-155.76M,-2.00,,350.3M,4.2,250.7M,1520.39,5.90,0.95,7.5M,-87.55M,Value,94080,Healthcare,184,6,9,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.",South San Francisco,650 624 3000,CA,7,1609372800,1625097600,4,United States,http://www.cytokinetics.com,86400,6,280 East Grand Avenue,650 624 3070,Biotechnology
t-1,CYTK,67846000.0,71738096,,,-47104000,,-47104000,15598000,-25013000,-40611000,-40611000,,-6783000,,,,0,6548000,47159000,31561000,-6493000,,-47104000,-47104000,1107135000.0,509216000.0,67846000.0,2438000.0,577062000.0,71000.0,-1039410000.0,255890000.0,50000.0,6396000.0,44594000.0,35930000.0,5625000.0,50000.0,102885000.0,433117000.0,34664000.0,380983000.0,4514000.0,131763000.0,7766000.0,1350000.0,-4047000.0,-5276000.0,-3596000.0,10497000.0,-38391000.0,-29519000.0,537000.0,-94000.0,-3596000.0,10692000.0,-6626000.0,-3596000.0,,397187000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,32.9,1630503360,-0.069999695,32.73,32.94,32.56,34479,-10.31348,0.948,28.89889,4.001112,0.1384521,24.313116,8.586885,0.35317913,2360183552,-10.64725,34.704643,15,America/New_York,EDT,False,False,USD,-3.19,us_market,"Cytokinetics, Incorporated",NMS,REGULAR,2,-0.2123133,32.56 - 32.94,32.97,32.0,34.51,18,31,finmb_27315,NasdaqGS,"Cytokinetics, Incorporated",USD,1812484,877283,18.190002,1.2365739,14.71 - 34.32,-1.4199982,-0.04137524,14.71,34.32,1620331200,1635872400,0,1636405200,-2.0,-3.09,-14400000,1.41,,,34.32,14.71,28.9,24.31,1.81M,877.28k,71.74M,,83.05M,4.76%,93.86%,11.41M,3.13,16.08%,13.67%,9M,,,,,,0.00%,,,1:6,"Jun 24, 2013","Dec 30, 2020","Jun 29, 2021",-269.48%,-219.08%,-19.87%,,57.8M,0.82,-20.90%,-41.12M,-124.54M,-155.76M,-2.00,,350.3M,4.2,250.7M,1520.39,5.90,0.95,7.5M,-87.55M,Value,94080,Healthcare,184,6,9,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.",South San Francisco,650 624 3000,CA,7,1609372800,1625097600,4,United States,http://www.cytokinetics.com,86400,6,280 East Grand Avenue,650 624 3070,Biotechnology
t-2,CYTK,113383000.0,71738096,,,-43930000,,-43930000,13908000,-22499000,-36407000,-36407000,,-9669000,,,,0,6722000,43129000,29221000,-7523000,,-43930000,-43930000,1105470000.0,420420000.0,113383000.0,1049000.0,533803000.0,70000.0,-992306000.0,253068000.0,149000.0,,82985000.0,31199000.0,,149000.0,22628000.0,474221000.0,36954000.0,381075000.0,6920000.0,135713000.0,8050000.0,-167063000.0,88312000.0,-173618000.0,3641000.0,-4124000.0,-117827000.0,52150000.0,471000.0,545000.0,-3596000.0,10876000.0,-6555000.0,-3596000.0,3641000.0,443022000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,32.9,1630503360,-0.069999695,32.73,32.94,32.56,34479,-10.31348,0.948,28.89889,4.001112,0.1384521,24.313116,8.586885,0.35317913,2360183552,-10.64725,34.704643,15,America/New_York,EDT,False,False,USD,-3.19,us_market,"Cytokinetics, Incorporated",NMS,REGULAR,2,-0.2123133,32.56 - 32.94,32.97,32.0,34.51,18,31,finmb_27315,NasdaqGS,"Cytokinetics, Incorporated",USD,1812484,877283,18.190002,1.2365739,14.71 - 34.32,-1.4199982,-0.04137524,14.71,34.32,1620331200,1635872400,0,1636405200,-2.0,-3.09,-14400000,1.41,,,34.32,14.71,28.9,24.31,1.81M,877.28k,71.74M,,83.05M,4.76%,93.86%,11.41M,3.13,16.08%,13.67%,9M,,,,,,0.00%,,,1:6,"Jun 24, 2013","Dec 30, 2020","Jun 29, 2021",-269.48%,-219.08%,-19.87%,,57.8M,0.82,-20.90%,-41.12M,-124.54M,-155.76M,-2.00,,350.3M,4.2,250.7M,1520.39,5.90,0.95,7.5M,-87.55M,Value,94080,Healthcare,184,6,9,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.",South San Francisco,650 624 3000,CA,7,1609372800,1625097600,4,United States,http://www.cytokinetics.com,86400,6,280 East Grand Avenue,650 624 3070,Biotechnology
t-3,CYTK,149605000.0,71738096,,,-3175000,,-3175000,12302000,17486000,5184000,5184000,,-9437000,,,,0,41688000,36504000,24202000,-8359000,,-3175000,-3175000,1096953000.0,324507000.0,149605000.0,2406000.0,474112000.0,70000.0,-948376000.0,160395000.0,958000.0,,200812000.0,27573000.0,,958000.0,14742000.0,418412000.0,40958000.0,209452000.0,4965000.0,134022000.0,6738000.0,-98431000.0,3818000.0,-101023000.0,226334000.0,4507000.0,139678000.0,14367000.0,536000.0,-2711000.0,-3596000.0,11392000.0,-2592000.0,-3596000.0,226334000.0,390839000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,32.9,1630503360,-0.069999695,32.73,32.94,32.56,34479,-10.31348,0.948,28.89889,4.001112,0.1384521,24.313116,8.586885,0.35317913,2360183552,-10.64725,34.704643,15,America/New_York,EDT,False,False,USD,-3.19,us_market,"Cytokinetics, Incorporated",NMS,REGULAR,2,-0.2123133,32.56 - 32.94,32.97,32.0,34.51,18,31,finmb_27315,NasdaqGS,"Cytokinetics, Incorporated",USD,1812484,877283,18.190002,1.2365739,14.71 - 34.32,-1.4199982,-0.04137524,14.71,34.32,1620331200,1635872400,0,1636405200,-2.0,-3.09,-14400000,1.41,,,34.32,14.71,28.9,24.31,1.81M,877.28k,71.74M,,83.05M,4.76%,93.86%,11.41M,3.13,16.08%,13.67%,9M,,,,,,0.00%,,,1:6,"Jun 24, 2013","Dec 30, 2020","Jun 29, 2021",-269.48%,-219.08%,-19.87%,,57.8M,0.82,-20.90%,-41.12M,-124.54M,-155.76M,-2.00,,350.3M,4.2,250.7M,1520.39,5.90,0.95,7.5M,-87.55M,Value,94080,Healthcare,184,6,9,"Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.",South San Francisco,650 624 3000,CA,7,1609372800,1625097600,4,United States,http://www.cytokinetics.com,86400,6,280 East Grand Avenue,650 624 3070,Biotechnology
